secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2025-05-05T23:59:59+00:00
Accession:  0000914475-25-000099
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine Q1: INGREZZA $545M (+8%), CRENESSITY $14.5M; GAAP EPS $0.08; reaffirms FY25 guide
--------------------------------------------------------------------------------

- INGREZZA net product sales $545M in Q1 2025, up 8% YoY; CRENESSITY sales $14.5M with 413 patient enrollment forms.
- GAAP net income $7.9M ($0.08 EPS) vs $43.4M ($0.42) YoY; Non-GAAP net income $71.5M ($0.70) vs $124.8M ($1.20).
- Reaffirmed 2025 INGREZZA net sales guidance of $2.5-$2.6B; total R&D guidance $960M-$1.01B GAAP.
- Initiated Phase 3 registrational programs for osavampator in MDD and NBI-568 in schizophrenia.
- Appointed Sanjay Keswani, M.D., as Chief Medical Officer effective June 2, 2025; authorized $500M share repurchase, $150M completed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000091447525000099/0000914475-25-000099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000091447525000099/nbix-20250505.htm
  HTML page:      https://secwatch.observer/filing/0000914475-25-000099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer